R&D channel feed – Endpoints News

R&D channel feed

Arena's lead drug misses on PhII in AD, thwacking stock, but company soldiers on into Phase III

5 years ago

Bristol Myers posts another win for their Otezla competitor, this time with PhII data in psoriatic arthritis

5 years ago

GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again

5 years ago

Newly Nasdaq-listed Calliditas surges after lead kidney drug hits primary endpoint

5 years ago

Sanofi hits the brakes on a top pivotal program following 'new adverse events'

5 years ago

Assembly Bio's hepatitis B program flops as a potential cure in PhII, sending shares spiraling

5 years ago

Latest J&J-partnered Legend Biotech data spotlight continued high response rate but 10 patient deaths

5 years ago

Bristol Myers hints at some problems with an FDA inspection needed for the liso-cel OK, and the Celgene CVR investors are panicking

5 years ago

What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on

5 years ago

Patient death mars latest cut of data from Allogene's off-the-shelf CAR-T

5 years ago

Amgen and Novartis back Aimovig with new data as migraine competition heats up

5 years ago

A year after stunning China OK, Shanghai Alzheimer's drugmaker set to enroll first US patient — and the stakes are huge

5 years ago

Vertex, fresh off an R&D miss, flashes data suggesting their sickle cell CRISPR therapy is working

5 years ago

With sales rising and efficacy questions swirling, Gilead faces calls to relinquish lucrative priority review voucher

5 years ago

PS: Did anyone at Biogen ask the FDA to pull an aducanumab conscientious objector off their expert panel? ‘No comment’

5 years ago

Jounce shares take a beating as their lead drug spurs only a weak response in PhII — trial halted

5 years ago

Bristol Myers wins a big bet as their PhIII autoimmune drug beat out blockbuster Otezla — and that could cost Amgen dearly

5 years ago

Can a darkhorse synthetic biology Covid-19 vaccine one-up the frontunners? The Gates Foundation, Amgen bet 'yes'

5 years ago

A little biotech's second crack at dry eye disease comes up short. And this time there will be no extra shot at success

5 years ago

Regeneron slams the brakes on rare disease trial following patient deaths — casting more doubt on a drug with mixed results

5 years ago

Santhera axes half its employees and sees CMO depart after PhIII DMD fail

5 years ago

Sanofi’s Paul Hudson pays $357M to buy a biotech partner, adding an NK strategy in the latest move to beef up cancer R&D

5 years ago

In a second big setback for Covid-19 antibody treatment hopes, Regeneron halts enrollment for more severe patients

5 years ago

In early blow to Kenji Yasukawa's R&D revamp, Astellas drops out of the TIGIT race, citing PhI failure

5 years ago

First page Previous page 183 184 185186187 188 189 Next page Last page